Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-10T22:28:22.693Z Has data issue: false hasContentIssue false

Chapter 5 - Oral dopamine agonists in the management of Parkinson's disease

from Section I - The Pharmacological Basis for Parkinson's Disease Treatment

Published online by Cambridge University Press:  05 March 2016

By
Javier Pagonabarraga ,
Juan Marín-Lahoz  and
Jaime Kulisevsky
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 34 - 47
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hornykiewicz, OD. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future. Neurology 1970; 20 (Suppl.): 1–5.Google Scholar
Cotzias, GC, Van Woert, MH, Schiffer, LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374–9.Google Scholar
Schrag, A, Quinn, N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297–305.CrossRefGoogle ScholarPubMed
Fabbrini, G, Brotchie, JM, Grandas, F, Nomoto, M, Goetz, CG. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379–89; quiz 1523.Google Scholar
Linazasoro, G. Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial. Arch Neurol 2007; 64: 137–40.Google Scholar
Nandhagopal, R, Kuramoto, L, Schulzer, M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011; 134: 3290–8.Google Scholar
de la Fuente-fernández, R, Schulzer, M, Mak, E, Calne, DB, Stoessl, AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004; 127: 888–99.Google Scholar
Hall, TR, Figueroa, HR, Yurgens, PB. Effects of inhibitors on monoamine oxidase activity in mouse brain. Pharmacol Res Commun 1982; 14: 443–53.Google Scholar
Dolphin, AC, Jenner, P, Sawaya, MC, Marsden, CD, Testa, B. The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents. J Pharm Pharmacol 1977; 29: 727–34.Google Scholar
Birkmayer, W. Long term treatment with l-deprenyl. J Neural Transm 1978; 43: 239–44.Google Scholar
Lees, AJ, Stern, GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981; 44: 1020–3.Google Scholar
Parkes, JD, Debono, AG, Marsden, CD. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976; 39: 1101–8.Google Scholar
Montastruc, JL, Rascol, O, Senard, JM, Rascol, A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034–8.Google Scholar
Rinne, UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826–8.Google Scholar
Schachter, M, Sheehy, MP, Parkes, JD, Marsden, CD. Lisuride in the treatment of Parkinsonism. Acta Neurol Scand 1980; 62: 382–5.Google Scholar
Massel, D, Suskin, N. Pergolide and cabergoline increased risk for valvular heart disease in Parkinson disease. ACP J Club 2007; 146: 75–6.Google Scholar
Van Camp, G, Flamez, A, Cosyns, B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179–83.Google Scholar
Zhou, CQ, Li, SS, Chen, ZM, Li, FQ, Lei, P, Peng, GG. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2013; 8: e69738.CrossRefGoogle ScholarPubMed
Voon, V, Sohr, M, Lang, AE, et al. Impulse control disorders in Parkinson disease: a multicenter case – control study. Ann Neurol 2011; 69: 986–96.Google Scholar
Weintraub, D, Koester, J, Potenza, MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.Google Scholar
NICE. Parkinson's disease: Diagnosis and Management in Primary and Secondary Care. NICE guidelines [CG35]. National Institute for Health and Care Excellence, 2011. Available at: https://www.nice.org.uk/guidance/cg35.Google Scholar
Miyasaki, JM, Martin, W, Suchowersky, O, Weiner, WJ, Lang, AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58: 11–7.Google Scholar
Pahwa, R, Factor, SA, Lyons, KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983–95.Google Scholar
Olanow, CW, Obeso, JA, Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677–87.CrossRefGoogle ScholarPubMed
Blanchet, PJ, Calon, F, Martel, JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995; 272: 854–9.Google Scholar
Bibbiani, F, Costantini, LC, Patel, R, Chase, TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005; 192: 73–8.Google Scholar
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000; 284: 1931–8.Google Scholar
Rascol, O, Brooks, DJ, Korczyn, AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–91.Google Scholar
Whone, AL, Watts, RL, Stoessl, AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93–101.Google Scholar
Katzenschlager, R, Head, J, Schrag, A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474–80.Google Scholar
Tan, EK, Jankovic, J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol 2001; 24: 247–53.Google Scholar
Tonini, M, Cipollina, L, Poluzzi, E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004; 19: 379–90.Google Scholar
Fox, S. Domperidone as a treatment for dopamine agonist-induced peripheral edema in patients with Parkinson's disease. ClinicalTrials.gov 2012; NCT00305331.Google Scholar
Gizer, IR, Ficks, C, Waldman, ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009; 126: 51–90.Google Scholar
Rashid, AJ, So, CH, Kong, MM, et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 2007; 104: 654–9.Google Scholar
van Wieringen, JP, Booij, J, Shalgunov, V, Elsinga, P, Michel, MC. Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 135–54.CrossRefGoogle ScholarPubMed
Zhang, J, Xiong, B, Zhen, X, Zhang, A. Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev 2009; 29: 272–94.Google Scholar
Yun, JY, Kim, HJ, Lee, JY, et al. Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease. BMC Neurol 2013; 13: 113.Google Scholar
Kvernmo, T, Härtter, S, Burger, E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065–78.Google Scholar
Tippmann-Peikert, M, Park, JG, Boeve, BF, Shepard, JW, Silber, MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68: 301–3.Google Scholar
Thobois, S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 2006; 28: 1–12.Google Scholar
Tomlinson, CL, Stowe, R, Patel, S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649–53.Google Scholar
Wright, CE, Sisson, TL, Ichhpurani, AK, Peters, GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 1997; 37: 520–5.Google Scholar
Clarke, CE, Speller, JM, Clarke, JA. Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000; 3: CD002261.Google Scholar
Moller, JC, Oertel, WH, Koster, J, Pezzoli, G, Provinciali, L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20: 602–10.Google Scholar
Lieberman, A, Ranhosky, A, Korts, D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162–8.CrossRefGoogle ScholarPubMed
Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66: 563–70.CrossRefGoogle Scholar
Inzelberg, R, Carasso, RL, Schechtman, E, Nisipeanu, P. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease. Clin Neuropharmacol 2000; 23: 262–6.Google Scholar
Herrero, MT, Pagonabarraga, J, Linazasoro, G. Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies. Neurologist 2011; 17 (Suppl. 1): S54–66.Google Scholar
Olanow, CW, Rascol, O, Hauser, R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.Google Scholar
Schapira, AH, McDermott, MP, Barone, P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013; 12: 747–55.Google Scholar
Ostow, M. Pramipexole for depression. Am J Psychiatry 2002; 159: 320–1.Google Scholar
Leentjens, AF, Koester, J, Fruh, B, et al. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009; 31: 89–98.Google Scholar
Rektorova, I, Rektor, I, Bares, M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399–406.Google Scholar
Barone, P, Poewe, W, Albrecht, S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–80.Google Scholar
Barone, P, Scarzella, L, Marconi, R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601–7.Google Scholar
Lemke, MR, Brecht, HM, Koester, J, Kraus, PH, Reichmann, H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005; 17: 214–20.Google Scholar
Kirsch-Darrow, L, Marsiske, M, Okun, MS, Bauer, R, Bowers, D. Apathy and depression: separate factors in Parkinson's disease. J Int Neuropsychol Soc 2011; 17: 1058–66.Google Scholar
Mayberg, HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997; 9: 471–81.Google Scholar
Kaye, CM, Nicholls, B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000; 39: 243–54.Google Scholar
Lieberman, A, Olanow, CW, Sethi, K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998; 51: 1057–62.Google Scholar
Rektorova, I, Balaz, M, Svatova, J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008; 31: 261–6.Google Scholar
Zagmutt, FJ, Tarrants, ML. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci 2012; 122: 345–53.Google Scholar
Kulisevsky, J, Pagonabarraga, J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf 2010; 33: 147–61.Google Scholar
Scheller, D, Ullmer, C, Berkels, R, Gwarek, M, Lubbert, H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 73–86.Google Scholar
Reynolds, NA, Wellington, K, Easthope, SE. Rotigotine: in Parkinson's disease. CNS Drugs 2005; 19: 973–81.Google Scholar
Guldenpfennig, WM, Poole, KH, Sommerville, KW, Boroojerdi, B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 2005; 28: 106–10.Google Scholar
Giladi, N, Boroojerdi, B, Korczyn, AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22: 2398–404.Google Scholar
LeWitt, PA, Lyons, KE, Pahwa, R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68: 1262–7.Google Scholar
Poewe, WH, Rascol, O, Quinn, N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513–20.Google Scholar
Trenkwalder, C, Kies, B, Rudzinska, M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90–9.Google Scholar
Ray Chaudhuri, K, Martinez-Martin, P, Antonini, A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013; 19: 660–5.Google Scholar
Ghys, L, Surmann, E, Whitesides, J, Boroojerdi, B. Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother 2011; 12: 1985–98.Google Scholar
Sarati, S, Guiso, G, Garattini, S, Caccia, S. Kinetics of piribedil and effects on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats. Psychopharmacology (Berl) 1991; 105: 541–5.Google Scholar
Emile, J, Chanelet, J, Truelle, JL, Bastard, J. Action of piribedil in Parkinson's disease: I.V. test and oral treatment. Adv Neurol 1975; 9: 409–13.Google Scholar
Lebrun-Frenay, C, Borg, M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin. 2002; 18: 209–14.Google Scholar
Ziegler, M, Rondot, P. [Action of piribedil in Parkinson disease. Multicenter study]. Presse Med 1999; 28: 1414–18 (in French).Google Scholar
Post, RM, Gerner, RH, Carman, JS, et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 1978; 35: 609–15.Google Scholar
Thobois, S, Lhommée, E, Klinger, H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136: 1568–77.Google Scholar
Nash, JR, Wilson, SJ, Potokar, JP, Nutt, DJ. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 2003; 61: 1161; author reply 1161.Google Scholar
Passouant, P, Besset, A, Billiard, M, Negre, C. [Effect of piribedil on nocturnal sleep (author's transl)]. Rev Electroencephalogr Neurophysiol Clin 1978; 8: 326–34.Google Scholar
Peralta, C, Wolf, E, Alber, H, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 2006; 21: 1109–13.Google Scholar
Frucht, S, Rogers, JD, Greene, PE, Gordon, MF, Fahn, S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908–10.CrossRefGoogle ScholarPubMed
Hauser, RA, Gauger, L, Anderson, WM, Zesiewicz, TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15: 658–63.Google Scholar
Etminan, M, Samii, A, Takkouche, B, Rochon, PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf 2001; 24: 863–8.Google Scholar
Paus, S, Brecht, HM, Koster, J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659–67.Google Scholar
Avorn, J, Schneeweiss, S, Sudarsky, LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005; 62: 1242–8.Google Scholar
Happe, S, Berger, K. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease – a prospective study. J Neurol 2001; 248: 1062–7.Google Scholar
Kleiner-Fisman, G, Fisman, DN. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol 2007; 64: 820–4.Google Scholar
Tan, EK. Peripheral edema and dopamine agonists in Parkinson disease. Arch Neurol 2007; 64: 1546–7; author reply 1547.Google Scholar
Senard, JM, Rai, S, Lapeyre-Mestre, M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 584–9.Google Scholar
Perez-Lloret, S, Rey, MV, Fabre, N, et al. Factors related to orthostatic hypotension in Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 501–5.Google Scholar
Kujawa, K, Leurgans, S, Raman, R, Blasucci, L, Goetz, CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000; 57: 1461–3.Google Scholar
Etminan, M, Gill, S, Samii, A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26: 439–44.Google Scholar
Onofrj, M, Thomas, A, D'Andreamatteo, G, et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci. 2002; 23 (Suppl. 2): S91–4.Google Scholar
Kamakura, K, Mochizuki, H, Kaida, K, et al. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline. Parkinsonism Relat Disord 2004; 10: 235–42.Google Scholar
Williams, DR, Lees, AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605–10.Google Scholar
Harding, AJ, Stimson, E, Henderson, JM, Halliday, GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002; 125: 2431–45.Google Scholar
Holman, AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 2009; 25: 425–31.Google Scholar
Almanzar, S, Zapata-Vega, MI, Raya, JA. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics 2013; 54: 387–91.Google Scholar
Schreglmann, SR, Gantenbein, AR, Eisele, G, Baumann, CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord 2012; 18: 207–9.Google Scholar
Avila, A, Cardona, X, Martin-Baranera, M, Bello, J, Sastre, F. Impulsive and compulsive behaviors in Parkinson's disease: a one-year follow-up study. J Neurol Sci 2011; 310: 197–201.Google Scholar
Mamikonyan, E, Siderowf, AD, Duda, JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008; 23: 75–80.Google Scholar
Dang, D, Cunnington, D, Swieca, J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol 2011; 34: 66–70.CrossRefGoogle ScholarPubMed
Ye, Z, Hammer, A, Camara, E, Munte, TF. Pramipexole modulates the neural network of reward anticipation. Hum Brain Mapp 2011; 32: 800–11.Google Scholar
Pondal, M, Marras, C, Miyasaki, J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2013; 84: 130–5.Google Scholar
Rabinak, CA, Nirenberg, MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58–63.Google Scholar
Nirenberg, MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30: 587–92.Google Scholar
Edwards, MJ. Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine ‘switch’. J Neurol Neurosurg Psychiatry 2013; 84: 120.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×